RxDoctor Payments Data

Gary Rylander, MD

Ophthalmology · Austin, TXNPI 1205831344

Payments from drug & device makers

$1,419in general payments, 2019–2025

Across 59 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$554
  • Aerie Pharmaceuticals, Inc.$142
  • Harrow Eye, LLC$128
  • Bausch & Lomb Americas Inc.$93
  • Novartis$84
  • Johnson & Johnson Surgical Vision, Inc.$73
  • plus $346 from 14 others

What the payments were for

  • Food & beverage$1,419100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,419 in reported general payments places this provider in the 40th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$111,636
Medicare patients
577
Services billed
1,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine38$14,775
RestasisCyclosporine12$11,787
Brimonidine Tartrate26$4,720
SimbrinzaBrinzolamide/Brimonidine Tart18$4,673
VyzultaLatanoprostene Bunod14$4,629
Latanoprost357$4,187
RocklatanNetarsudil Mesylat/Latanoprost12$4,071
Travoprost17$3,258
Fluorometholone25$1,970
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat97$1,671
Prednisolone Acetate26$963
Timolol Maleate46$620
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha23$244
ErythromycinErythromycin Base20$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$554$11,78712 claims
AlconSimbrinza$27$4,67318 claims
Bausch & Lomb Americas Inc.Vyzulta$93$4,62914 claims
Aerie Pharmaceuticals, Inc.Rocklatan$142$4,07112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →